anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention relates to a painless bonesetting medicine, particularly to a formula for treating patient&#39;s tendon and bone injury, which is successful through perennial medicine research and clinical experiments. The present invention is prepared from various Chinese herbal medicines. The treating way mainly adopts an external application way and an oral administration medicine way, manipulation is additionally carried out, and the effect is good. The medicine has the effect on sterilization, inflammation relieving, tissue regeneration promotion, pain alleviating, stasis breaking, coaptation, tendon connection, etc. when the bonesetting is carried out, a patient can not feel pain and insensible, and no side effect exists. Thousands of clinical tests indicate that the patient with large-sized fracture can get off the bed for movement after one week and can recover after four to five weeks, and the original shape can be recovered.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and can be used for treating patients with olfactory dysfunction in atrophic rhinitis. Method includes preliminary diagnosing of olfactory function disorder with calculation of total score by &#34;Sniffin&#39; Sticks Test&#34;. If total test score is 1–15 points, functional anosmia – residual ability to olfaction is diagnosed, at 16–30 points, hyposmia – smell reduction – is diagnosed. Treatment of olfactory dysfunction involves: irrigation therapy – washing the nasal cavity with 0.9 % NaCl physiological solution in amount of 5–10 ml for 5 minutes daily 2 times day for 3 weeks; olfactory training using rose oil, eucalyptus, lemon and cloves, which are brought to vestibule for 10 seconds for each, with interval of 10 seconds for 84 to 252 days. Simultaneously, a medicamentous therapy with Neuromidine is used. In functional anosmia with total test score of 1–15 points by intramuscular introduction in amount of 5 to 15 mg/ml 1-2 times day for 10 days, followed by treatment with Neuromidine 1 tablet 10 to 20 mg 3 times day for 28 days. If hyposmia with total test score of 16–30 points by intramuscular introduction in amount of 5 mg/ml 2 times day for 10 days, followed by treatment with Neuromidine 1 tablet 10 to 20 mg 2 times day for 28 days.EFFECT: method enables higher clinical effectiveness in olfactory dysfunction by acting on peripheral olfactory tract, and stimulation of olfactory epithelial cell regeneration by olfactory trainings and using Neuromedin preparation, which has a direct stimulating effect on the impulse as per the nerve fiber.1 cl, 2 dwg, 1 ex
A system and method for including and correcting subject orientation data in a digital radiographic image. A subject (14) is positioned in an X-ray imaging system (10) and an orientation of the subject (14) is entered into the X-ray imaging system (10). The subject is imaged with an X-ray exposure to create an X-ray image (12) of the subject (10). An operator reviews the X-ray image (12) of the subject (12) and subject orientation data. If the subject orientation data is not correct, the operator may correct the subject orientation data so that it matches the subject&#39;s anatomy during the X-ray exposure. The correct subject orientation data is then saved and is part of the X-ray image (12) and Digital Imaging and Communications in Medicine (DICOM) header when sent to a Picture Archiving and Communication System (PACS).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a stable cosmetic which has an excellent antibacterial property, safety, and usability, and exhibits transparent fluidity in a wide pH range and in a wide ingredient composition range.  &lt;P&gt;SOLUTION: A colloid liquid obtained by dispersing ultra fine silver particles having an average particle diameter of 1 to 5 nm in water is formulated into a cosmetic as an antibacterial ingredient. For example, a colloid liquid containing the ultra fine silver particles in an amount of 20 ppm based on weight is formulated into a cosmetic such as a lotion or a milky lotion in a concentration of 0.5 to 30 wt. %. The employment of the antibacterial ingredient gives a sufficient antibacterial activity, excellent storage stability and excellent liquid properties to even a lotion containing collagen in a high concentration, and the cosmetic scarcely irritates skins and gives an unpleasantness.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
Novel quinoline derivatives of formula &lt;FORM:1070223/C2/1&gt; wherein R1 is an alkyl, aryl or aralkyl group which may be substituted by halogen, nitro, or alkyl substituents; R2 is an alkyl radical, and wherein the quinoline nucleus may be additionally substituted by alkyl, alkenyl, alkoxy or halogen substituents, provided that when the quinoline nucleus bears no additional substituents and when R2 is the ethyl radical, R1 is not the methyl or phenyl radical, and provided that when both R1 and R2 stand for C1- 4 alkyl radicals, then the quinoline nucleus does not bear as sole additional substituent, a C1- 4 alkoxy radical, are prepared by (a) cyclization of a compound of the formula &lt;FORM:1070223/C2/2&gt; for example by heating; (b) esterification of the acid formed from the ester of Formula (I), or (c) halogenation of a compound of Formula (I) using an N-halogenated amide.  The acids referred to in (b) above may be prepared by hydrolysis of compounds of Formula (I) under acidic or basic conditions.  Compounds of Formula (II) are prepared by reaction of a dialkyl alkoxy methylene malonate with the appropriate aniline derivative substituted in the 3-position by an R1O- group.  3 - Benzyl - oxy - 4 - ethoxy - and 3 - benzyloxy - 4 - propoxyanilines are prepared by refluxing the corresponding nitrobenzene derivatives with sodium sulphide in ethanol. 3-(4-Methylphenoxy)-aniline is prepared by reaction of p-cresol with m-bromo aniline in the presence of copper bronze and KOH.  3-Substituted aniline derivatives are prepared by the hydrolysis of the corresponding 3-substituted acetanilide derivatives which in turn are prepared by reaction between a 3-hydroxy-acetanilide and a halide R1Hal, in the presence of potassium carbonate and acetone.  3-Hydroxy-4-methallyl - acetanilide is prepared by reacting 3-acetyl-aminophenol with crotyl bromide to form 3-crotyloxy-acetanilide which is then rearranged by refluxing in N,N-dimethylaniline. 3 - Cinnamyl - oxy - acetanilide is prepared by reacting 3-acetylaminophenol with cinnamyl chloride and hydrogenating to give 3-(3-phenylpropoxy)-acetanilide  3-Benzyloxy - 4 - ethoxynitrobenzene and 3-benzyloxy - 4 - ethoxynitrobenzene are prepared by reaction of the corresponding 4-hydroxy derivatives with ethyl chloride and n-propyl iodide respectively.  Veterinary compositions, useful for the prophylactic treatment of coccidiosis, comprise compounds of Formula (I) above with a non-toxic diluent or carrier.  They may be, for example, concentrated food pre-mixes wherein the active ingredient is mixed with an inert diluent, or a foodstuff diluent, e.g. whole ground corn, corn distillers grain, wheat shorts or corn cob meal.  The compositions may also contain compounds of known veterinary utility, e.g. anthelmintics or growth promoters, anti-bacterials or tranquillizers.
Embodiments herein relate to hearing assistance devices and related systems and methods for providing visual feedback to a subject undergoing physical therapy or vestibular movement training. In an embodiment, a method of providing physical or vestibular therapy to a subject is included. The method can include prompting the subject to move in a predetermined direction by a predetermined amount as part of a first predetermined movement. The method can further include tracking movement of the subject using a first IMU disposed in a fixed position relative to the subject&#39;s head. The method can further include generating feedback data by comparing the tracked movement of the subject against the predetermined direction and amount of the first predetermined movement. The method can further include generating a feedback image using the feedback data. Other embodiments are included herein.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new protein CERAIN effective for controlling the secretion of a neurotrophic factor and provide its gene.  &lt;P&gt;SOLUTION: The protein of the present invention is present at the presynaptic moiety of Purkinje&#39;s cells in the parallel fiber of a granulocyte and participates in the secretion of neutrotrophic factor. The neurotrophic factor is supposed to participate also in the activity-dependent synaptic plasticity and the protein of the present invention is effective for reinforcing the nerve circuit. Based on the above findings, the present invention relates to a substance usable for the detection and analysis of CERAIN gene and protein such as a PCR primer specifically amplifying CERAIN gene, a probe specifically detecting the gene and an antibody against CERAIN protein. The invention further relates to a screening method for a substance effective for controlling the function of CERAIN protein, the substance obtained by the screening method and a pharmaceutical composition for the prevention and/or treatment of diseases necessitating the secretion control of neurotrophic factor.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
814,259. Producing solid drops from molten materials. EASTMAN KODAK CO. March 28, 1956 [April 15, 1955], No. 9641/56. Class 87(2). Uniformly-sized beadlets of a normally solid, fusible, organic material are produced by extruding the material under a pressure between 50 and 250 lb. per square inch, substantially free of unfused material, through capillary bores between 0À001 and 0À015 inches diameter into a gaseous cooling medium in liquid streams of substantially uniform cross-section. The molten material is pumped from a heated tank 10 to extrusion heads 19, each of which comprises a housing 32 with an outlet wall comprising a die plate 34 held in place by a cap 36 with a bayonet coupling. The inlet includes filtering media 40, e.g. cotton wadding, retained by a fine mesh screen 39. Drawn stainless steel capillary tubes form the die orifices 42 which may be of various diameters. As the extruded streams of material descend in a tubular structure 23 they become beadlets, which encounter a stream of cooling gas (air, nigtroen, or carbon dioxide) blown upwards through louvres 27 ; or alternatively in the same direction as the stream. The beadlets are collected through a duct 29 with a gate 30. On its way to the extrusion head the material, impelled by a pump 16, passes through a strainer and filter 15, 18 and regulating valve 21, 22. Typical materials are mineral and vegetable waxes, solid fatty materials e.g. lard, tallow and esters of glycerine, to which may be added stabilizers or antioxidants e.g. butylated hydroxy anisole &amp;c. Numerical examples are given of the formation of beadlets from a mineral microcrystalline wax and from a monoester of glycerine.
NEW MATERIAL:A low molecular protein having the following properties. Molecular weight, 13,000+ or -1,500; isoelectric point, 4.0+ or -0.3 pH; peak of UV absorption in 0.02M tris-HCl buffer solution added with 0.1M NaCl(7.8 pH), 278nm, the lowest point of the absorption 252 nm; the solution obtained by dissolving 3mg of the protein in 1ml of 0.02M tris-HCl buffer solution (7.8 pH) is colorless and transparent; addition of &gt;=70V/V% of acetone, etc. to the solution causes precipitation; the aqueous solution is weakly acidic; color reactions of peptide bond and amino acid, positive to biuret reaction, Folin-Lawry reaction, etc. USE:A carcinostatic agent. It exhibits direct cytotoxicity to the cultured mouse L-cell in vitro, and exhibits antitumor activity against female mouse affected with A sarcoma in vivo. PROCESS:A substance having immunoactivating activity is administered to a mammal, then an endotoxin originated from Gram-negative bacteria or lectin originated from vegetable is administered thereto to induce and produce the objective low molecular protein.
One aspect of the present invention provides for a process and method of management of fitness, health and/or wellness specialist services based on the time needs and/or wants of an individual. This aspect comprises the steps of creating an account balance of specialist minutes by purchasing a block of specialist minutes on a per unit cost; using the specialist services for a period of minutes based on the needs of the individual; then reducing the account balance by the period of minutes previously used. This allows for more control by the individual over the amount of time spent on specialist services. Further the present inventive method allows for the tracking of the specialist minutes by an individual. This aspect allows for the tracking of an individual&#39;s specialist time usage. This allows for the improved monitoring individual health programs, along with the monitoring of a specialist&#39;s time, which can lead to greater effective health programs for the individual and more efficient usage of a specialist&#39;s time.
Bacterial toxins for subcutaneous and like injection are incorporated in a fine emulsion of a fatty oil or fat so as to be adsorbed on the dispersed particles of the oil or fat.  The toxin may be added to the emulsion or the oil &amp;c., may be emulsified in an aqueous medium containing the toxin.  The diameter of the oil particles in the emulsion is preferably about 1/2 m , and should not exceed 1 1/2 m , and the emulsion may be made by means of the apparatus described in Specification 323,534, [Class 81 (i)], operating at a pressure of 3000 to 4000 lbs., per sq. inch.  Endotoxins for use in the process may be prepared by a preliminary passage of a suspension of bacteria through the emulsifier so as to disrupt the bacteria and release the toxins; alternatively the bacteria may be disrupted by other mechanical means, or solutions of bacteria prepared according to Specification 425,216 may be used.  The emulsion may be one containing from 5 to 30 per cent of olive oil emulsified by means of sodium carbonate and oleic acid or by means of gum acacia; it may be adjusted to pH 7,4 to 8,0, and may be sterilized at 60 DEG  C. Phenol may be added to the continuous phase or to the finished emulsion.  Specification 417,715 also is referred to.
PURPOSE:To prepare the titled compound useful as a synthetic intermediate of a spergualin-mimic compound useful as a carcinostatic agent, by the selective oxidative scission of the corresponding C-C bond of a compound such as N-seryl- spermidine, etc. CONSTITUTION:The objective compound of formula II can be prepared by the oxidative scission of the corresponding C-C bond of the compound of formula I (R&lt;1&gt; is OH or NH2 provided that all R&lt;1&gt; are not NH2 at the same time; R&lt;2&gt; is H or alkyl, carboxyl, etc. which may have substituent group). The compound of formula I gives the objective compound by the oxidative scission irrespective of the substituent group of R&lt;2&gt;. For example, N-seryl-spermidine of formula IIIwherein R&lt;1&gt; is NH2 and OH and R&lt;2&gt; is H can be prepared by reacting the compound of formula I with periodic acid as the oxidative scission reagent usually in an aqueous solution. Other examples of the compound of formula I usable as a substrate is the compound of formula IV and formula V.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a further improved vesicle preparation and method for preparation therefor.  &lt;P&gt;SOLUTION: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titers than OMVs prepared by normal production processes. Thus, a bacterium having a knockout mutation of its mltA gene is provided. A bacterium is also provided, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity of MltA protein. Compositions comprising vesicles are also provided that, during culture of bacteria, vesicles are released into the culture medium.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention relates to the field of treatment of sepsis, specifically to a medicine capable of reducing mortality and relatively prolonging survival time. It is found through current researches that a forsythia extract has effects of destroying bacterial endotoxin and inhibiting various positive and negative bacteria. But the mechanism of action hasn&#39;t been completely illustrated clearly, thus affecting the promotion of the forsythia extract to the international market. By silica gel column chromatography, Saphadex LH-20 column chromatography, recrystallization and the like, the substance is separated from 50% forsythia ethanol extract. By chemical identification, H NMR spectroscopy, C NMR spectroscopy, thin-layer chromatography, high performance liquid chromatography and the like, structural identification is carried out on a substance, and its structure and name are determined. By replication of cecal ligation perforation animal model, the pathological process of human sepsis is simulated. Tail vein injection is carried out for drug delivery, and postoperative survival rate of rats is observed after operation. According to the invention, forsythin is used as a main component to prepare an injection which is used for treatment of sepsis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a function allowing a consumer to create or correct a self image according to its recognition of reality.  &lt;P&gt;SOLUTION: A method and an apparatus for correction of the body image can be used for a target person to correct the body image of the target person based on the self evaluation of an actual state of a body of the target person itself. It is possible for the target person to be encouraged to capture a primitive body image by using an image capturing apparatus. It is also possible for the target person to be encouraged to execute the self evaluation of the actual state of the body of the target person itself. It is possible for the primitive body image to be corrected so as to reflect the self evaluation of the target person based on his reaction to the encouragement for the self evaluation.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
NEW MATERIAL:Pfaffic acid and its derivative of the formula (R1 is H or acyl; R2 is H or alkyl). USE:An antitumor agent, capable of exhibiting improved inhibitory activity against melanoma cells, cervical cancer cells, cancer cells of the lung, etc. in a concentration as low as 4-6mug/ml, and administered in 10mg-1g, preferably about 100mg daily dose in the form of a powder, granule, capsule, solution, etc. PROCESS:The root of a dried Pfaffia paniculate Kuntze is pulverized and extracted with an alcohol, and sulfuric acid is then added to the resultant extract solution and refluxed under heating to distill away the solvent. The residue obtained by the distillation is then passed through a column packed with silica gel, and eluted with a mixture of chloroform with methanol at (50:1)-(20:1) ratio. The solvent is then distilled from the eluted fraction to recrystallize the residue from the alcohol and give the aimed pfaffic acid of the formula. The pfaffic acid of the formula is a crystalline substance having specific &lt;=29C skeleton, and stable to acids and alkalis with 285-286 deg.C melting point.
FIELD: medicine. ^ SUBSTANCE: invention concerns medicine, namely neurology and can be used for treating infantile cerebral paralysis (ICP). The method is implemented as follows: when detecting a mixed infection, there is determining its sensitivity to antibacterial preparations. It is followed with myeloexfusion of bone marrow to recover mononuclear leukocytes; the recovered fraction of mononuclear leukocytes is irradiated with a helium-neon laser light of the power 2.0 mWt during 15 minutes. Further, an etiotropic antibacterial preparation is adsorbed on these mononuclear leukocytes in a daily dosage considering the patient&#39;s age and body weight and introduced intravenously. Therapeutic procedure is daily within 5-7 days; additionally hepatoprotectors, immunomodulators and dysbacteriosis preventive agents are administered. ^ EFFECT: application of the invention allows improving clinical effectiveness in relation to ICP due to the reparation of tissues exposed to infection by the directed antibiotics delivery through hematoencephalic barrier into the centre of neuroinfection. ^ 1 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new member of tumor necrosis factor (TNF) family of cytokines, concretely an isolated nucleic acid molecule encoding an endokine α protein.  &lt;P&gt;SOLUTION: There are provided a new member of the tumor necrosis factor (TNF) family of cytokines, in particular, isolated nucleic acid molecules encoding the endokine α protein. There are also provided endokine α polypeptides, vectors, host cells and recombinant methods for producing these substances. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders. The method includes a step to administer an individual with a therapeutically effective amount of the endokine α polypeptide or a step to administer an individual with a therapeutically effective amount of an endokine α antagonist.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention incorporates a network and modules to register and monitor a group leader and a plurality of participants for a specific group activity, each remotely located from each other and a group physiological state server. Each of a plurality of module and individual registration information of each participant is stored in the form of data in memory on the server and individual participant data is stored at each participant&#39;s location. The second module monitors and processes real-time physiological measurements for each of the participants in the specific group activity. A third module tracks a physiological state of the participants, and fourth module evaluates and applies artificial intelligence to provide real-time feedback concerning the physiological state of the group or of an individual. A fifth module may also be employed to provide feedback pertaining to the group leader&#39;s physiological state in relation to the overall group physiological state.The Smart Meditation and Physiological system invention is an advanced group meeting network where meditation brain waves, alpha-meditation and stress, beta-concentration and intellectual activity, gamma-focus and engagement, theta-attention span (such as if subscribers are drifting off to sleep during a session) are recorded and analyzed, yielding collective neurological information to guide the host, physician, instructor, or motivational speaker real-time feedback during a group session.Moreover, the invention aids in evaluating and facilitating group meditation and yields emotional information of one or more individual participants to monitor the effectiveness of an individual and or group meeting, or a religious prayer session, as well as providing physiological information. It is also a health maintenance diagnostic system all-in-one that continually monitors the health of each individual user in real-time and provides an overall assessment of the effectiveness of the session, a media presentation, or a group meeting, and the information is easily accessible to the host and or to all parties within the group, if desired, housed in a cloud-based system. The information allows the instructor, clergy, or host to perfect and or curtail their next sermon, conference, class, or motivation talk to a particular audience.